Wedbush cuts ORIC Pharmaceuticals target price to $14 from $17
ORIC•Wedbush cut its target price for ORIC Pharmaceuticals to $14 from $17.
Related News
HUTCHMED hosts expert webcast on savolitinib Phase III data in lung cancer
HCM•
Asian stocks surge as Anthropic IPO lifts sentiment ahead of earnings, central banks
SPY•
Dark Mirage reports acquisition of $1.16 million in Optimum Communications common shares
OPTU•
Business First Bancshares Inc: D.A. Davidson raises target price to $39 from $35
BFST•
Blackstone opens Bengaluru office, expanding India presence
BX•